AIM Banners_978 x 90

NVIDIA’s GenAI for Healthcare Takes Center Stage at GTC 2024

Healthcare giants like Amgen, Astellas, DNA Nexus, and Iambic Therapeutics leverage these microservices to improve drug discovery and antibody design using generative AI. 
NVIDIA’s GenAI for Healthcare Takes Center Stage at GTC 2024
Healthcare has always been one of NVIDIA's bigger bets. And now, exactly on the one-year anniversary of BioNeMo cloud, the company has introduced a set of over 25 new generative AI-powered microservices to empower healthcare organisations globally across various domains, such as drug discovery, medical technology (MedTech), and digital health, at the much-awaited NVIDIA GTC 2024.  Additionally, BioNeMo now contains new foundational models for various tasks in drug discovery, such as analysing DNA sequences, predicting protein structure changes caused by drug interactions, and identifying cell functions from RNA data.  “Healthcare is inherently complicated. We aim to make it easier for researchers who can fine-tune these models on proprietary data, run AI model inference throu
Subscribe or log in to Continue Reading

Uncompromising innovation. Timeless influence. Your support powers the future of independent tech journalism.

Already have an account? Sign In.

📣 Want to advertise in AIM? Book here

Picture of Shritama Saha
Shritama Saha
Shritama (she/her) is a technology journalist at AIM who is passionate to explore generative AI with a special focus on big techs, database, healthcare, DE&I, hiring in tech and more.
Related Posts
AIM Print and TV
Don’t Miss the Next Big Shift in AI.
Get one year subscription for ₹5999
Download the easiest way to
stay informed